Postoperative fibrinolysis in inherited bleeding disorders

  • Research type

    Research Study

  • Full title

    To assess the postoperative changes in fibrinolysis and the utility of tranexamic acid in patients with inherited bleeding disorders.

  • IRAS ID

    295131

  • Contact name

    Beverley Hunt

  • Contact email

    beverley.hunt@gstt.nhs.uk

  • Sponsor organisation

    Guys and St Thomas's Foundation NHS Trust

  • Duration of Study in the UK

    0 years, 11 months, 29 days

  • Research summary

    Previous studies have shown that 24 hours after surgery the process of clot breakdown (fibrinolysis) shuts down. Tranexamic acid is a medication which inhibits fibrinolysis. Despite this, for many years patients with an inherited bleeding disorder have been given tranexamic for 5 days postoperatively. We hypothesize that use of tranexamic acid, beyond 24 hours post-operatively is unnecessary. We aim to perform a prospective trial assessing (a) laboratory markers of clot break down and (b) the effect of one versus five days of tranexamic acid in patients with inherited bleeding disorder.

  • REC name

    London - Camden & Kings Cross Research Ethics Committee

  • REC reference

    22/LO/0034

  • Date of REC Opinion

    4 Feb 2022

  • REC opinion

    Favourable Opinion